The complete nucleotide sequence of a antigen secreted from Mycobacterium avium (A-a) 
A protein designated a antigen was first isolated from the culture filtrate of Mycobacterium tuberculosis (T-a) by Yoneda and Fukui (36) . Analogous antigens were studied independently by different investigators and given different designations. MPB59, antigen 6, and BCG 85B are identical to a antigen (15, 31) . BCG 85 complex consists of three structurally related components, A, B, and C (30, 32) . BCG 85A is identical to P32 (9) . The~gene for a antigen was first cloned by us from Mycobacterium bovis BCG (18) and Mycobacterium kansasii (17) . The analogous gene was recently cloned from Mycobacterium leprae (16, 28) . The genes for the 85A component were cloned from M. tuberculosis (4) and M. bovis BCG (10) . The gene for the 85C component was cloned from M. tuberculosis (8) .
Since antigen 85 complex is produced early in the growth phase (3) and in large amounts (20 to 30%), it may play an important physiological role in immunopathology. Indeed, these proteins are a major stimulant of cellular and humoral immunity (2, 8, 29, 31) ; binding to fibronectin (1, 21, 28) and the induction of gamma interferon synthesis (13, 14) have been reported.
The Mycobacterium avium-Mycobacterium intracellulare complex was rarely identified as a cause of severe infections in humans until recently (6, 7, 33) . However, it has recently been recognized that the M. avium-M. intracellulare complex is a frequent opportunistic pathogen in patients with AIDS (5, 19) . In the present study, cloning, sequencing, and B-cell epitope mapping of the gene encoding a antigen secreted from M. avium (A-a) were performed.
MATERIALS AND METHODS
Bacterial strains and plasmids. The bacterial strains and plasmids used are presented in Table 1 . M. avium ATCC 15769 was grown in Sauton medium (24) . Escherichia coli K-12 strain JM109 was used as a host for plasmids pUC18, pUC19, and their derivatives, and strain EQ192 was used as a host for plasmids pUR291, pUR278S, pUR289S, and their * Corresponding author.
derivatives. E. coli JM109 and EQ192 were grown in the NZYM medium (1% NZ amine, 0.5% yeast extract, 0.5% NaCl, and 0.2% MgSO4. 7H20) (23) .
Media and reagents. NZYM medium and NZYM plates containing 100 jig of ampicillin per ml were used for growing E. coli K-12 strains. All enzymes, pUC18 and pUC19 vectors, the nick translation kit, the 7-deaza sequencing kit, and the DNA ligation kit were purchased from Takara Shuzo Co., Ltd. (Kyoto, Japan). [a-P]dCTP and the ECL direct nucleic acid labelling and detection system were from Amarsham Japan Co., Ltd. (Tokyo, Japan). Peroxidase-conjugated swine anti-rabbit immunoglobulin was purchased from Dakopatts Co., Ltd. (Glostrup, Denmark).
Amino acid sequencing. A-a was purified from M. avium as described previously (25) . About 30 ,ug of purified A-a was analyzed by a model 470A gas-phase protein sequencer (Applied Biosystems, Foster City, Calif.), and the N-terminal 18-amino-acid sequence was determined.
DNA technology. Unless otherwise stated, standard procedures were used for the preparation and handling of DNA (23) .
Preparation of probes. As nucleotide probes, two parts of the a antigen gene of M. bovis BCG were used. One was a 0.7-kbp PstI fragment containing the N-terminal end of the gene (probe A). The other was a 0.3-kbp XhoI-PstI fragment containing the C-terminal end of that gene (probe B) (18) . For genomic Southern hybridization, probes were labelled by using an ECL direct nucleic acid labelling system as described in the manufacturer's instructions. For colony hybridization, approximately 1 ,ug of fragments was nick translated by using a nick translation kit and [a-32P]dCTP (3,00OCi/mmol) as described previously (18) .
Genomic Southern hybridization. M. avium DNA was prepared as described previously (24) . SphI digests of approximately 1 Fig. 3 . PstI fragments from the mycobacterial DNA insert were subcloned into the PstI site of pUC18. In the same way, KpnI fragments were subcloned into the KpnI site, Sau3AI fragments were subcloned into the BamHI site, TthHB8I fragments were subcloned into the AccI site, KpnI-SphI fragments were subcloned into the KpnI-SphI site, and BamHI-SphI fragments were subcloned into the BamHI-SphI site of pUC18 or pUC19. The nucleotide sequences of these subcloned fragments were determined by the dideoxy chain termination method (12) . Additionally, synthetic primers were used so that the complete sequencing was done by using overlapping fragments on both strands. the BamHI-HindIII site of pUR291, giving rise to pMAA10. Recombinant plasmid pMAA12 was constructed by subcloning the 161-bp Sau3AI-HindIII fragment of pAABR250 into the BamHI-HindIII site of pUR292. The 800-bp EcoRIScaI fragment from pAAP08 was subcloned into the EcoRI-HincII site of pUC18, giving rise to pAAESc800. To construct plasmid pMAA13, the recombinant plasmid pAAES-c800 was digested with RsaI-HindIII. The 165-bp RsaI-HindIII fragment was subcloned into the SmaI-HindIII site of pUR278S. The 248-bp Sau3AI-PstI fragment from pAAP08 was subcloned into the BamHI-PstI site of pUR292, resulting in plasmid pMAAll. The 40-bp ScaI-PstI fragment from pAAP08 was subcloned into the SmaI-PstI site of pUR278S, resulting in plasmid pMAA14.
Construction of pMAA9 mutants. Oligonucleotides were synthesized automatically with a DNA synthesizer (model 380A; Applied Biosystems) and purified by two cycles of reverse-phase liquid chromatography. The sequences encoding 318-LeuGlnGlyThr LeuGlyAlaSerArgGlyGlyGlyGly-330 were 5'-GGGCACGCTGGGCGCGTCCCGGGGCGGCGG CGGATA-3' for the upper strand and 5'-AGCITATCCGCC GCCGCCCCGGGACGCGCCCAGCGTGCCCTGCA-3' for the lower strand, and those encoding 318-LeuGlnGlyThrLeu GlyAlaSer-325 were 5'-GGGCACGCTGGGCGCGTCCTA-3' for the upper strand and 5'-AGC`llAGGACGCGCCCAG CGTGCCCTGCA-3' for the lower strand. Those sequences were cloned into the PstI-HindIII site of the pUR291 vector. The resulting plasmids were named pMAA91 (the former sequences) and pMAA92 (the latter sequences), respectively.
Production of recombinants. The expression of lacZ-A-a hybrid genes from plasmids pMAAl-14 and pMAA91-92 were carried out by transforming the plasmids into E. coli EQ192. The cells harboring plasmids were cultured in 10 ml of NZYM broth containing 50 ,ug of ampicillin per ml at 37°C to an optical density at 600 nm of 0.6, isopropyl-p-Dthiogalactopyranoside was added at 1 mM, and an additional 1.5 h of incubation followed. After cells were harvested and sonicated, the lysates were obtained by centrifugation. The production of proteins was analyzed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). Gels containing 12.5% acrylamide were used. Western blotting (immunoblotting) was carried out as previously described (18) .
Immunological techniques. Polyclonal antibodies raised against A-a, a antigen of M. kansasii (K-a), and T-a were prepared as previously described (26) . The absorbed anti-A-a serum was prepared by absorption with the same volume of partially purified T-a (26) . Contaminating reactivities to bacterial antigens were removed from sera by absorption with bacterial cells lysed by boiling.
Mapping of B-cell epitopes. The reactivities of unabsorbed and absorbed anti-A-a sera with various LacZ-A-a fusion proteins and LacZ-mutated A-a fusion proteins were determined by Western blot analysis (18) . In the same way, the reactivities of anti-K-a and anti-T-a sera with pMAA2 and pMAA7-14 were deternined.
Nucleotide sequence accession number. The nucleotide sequence of the A-a gene has been entered at the EMBL data library under accession number X63437. RESULTS N-terminal amino acid sequence. The N-terminal amino acid sequence of A-a is given in Fig. 1 regions of the a antigens (antigen 85 complex B components of mycobacteria) of M. bovis BCG (18) and M. leprae (16, 28) and of K-a (17). They were also identical to antigen 85 complex A components of M. tuberculosis or M. bovis BCG (4, 10) and antigen 85 complex C components of M. tuberculosis (8) .
Southern hybridization analysis. Genomic Southern hybridization was carried out with either probe A or probe B. We obtained three SphI-digested DNA fragments (5.6, 4.9, and 3.6 kbp) clearly hybridized with both probes A and B. Two additional weak bands (8.4 and 6.7 kbp) of lower optical density were seen with probe A but not with probe B (Fig.  2) . The 5.6-kbp fragments which most strongly hybridized with both probes A and B were cloned and used for further study. The location of the a gene is shown with a restriction map in Fig. 3 .
Nucleotide and amino acid sequencing. The 1,236-nucleotide sequence and the deduced 330-amino-acid sequence are shown in Fig. 4 Mapping of B-cell epitopes on A-a. To localize the B-cell epitopes of A-a, a series of deletion constructs were produced from pAASp56 by using restriction enzymes which allowed expression of A-ao sequences in transformed E. coli cells (Fig. 6) . The resultant recombinants were analyzed by SDS-PAGE and Western blotting with both unabsorbed and absorbed sera raised against the purified A-a, and the results are presented in Fig. 7 . The unabsorbed serum detected the fusion proteins coded by plasmids pMAA2-5 and pMAA7-9 ( Fig. 8) , whereas the absorbed serum detected only the fusion proteins coded by plasmids pMAA3 and pMAA7-9 (Fig. 9) . These results indicated that the M. avium protein carries at least two epitopes specific for M. avium in the Gly-169 to Gln-319 and Leu-318 to Gly-330 amino acid sequences. Both anti-K-a and anti-T-at sera detected the fusion proteins coded by plasmids pMAA2, pMAA7, and pMAA8 but not that of pMAA9 (data not shown). These results indicated that A-ao protein also carries at least two B-cell epitopes in the Leu-51 to was less than that with unabsorbed serum. The plasmid pMAA12 (Ile-204 to Tyr-250) did not react with both sera. All of these data combined with the conclusion described above suggested that each region might contain one more epitope unrelated to M. kansasii and M. tuberculosis.
DISCUSSION
Three closely related immunodominant antigens, 85A, -B, and -C, with molecular masses of 32, 30, and 33 kDa, respectively, are known in M. bovis BCG and M. tuberculosis. DNA analysis revealed that these antigens constitute a gene family. Among them, antigen 85B corresponds to the a antigen. To clone the gene encoding A-a, Southern hybridization analysis was performed with two kinds of probes. The probe DNA encoding the C-terminal end of the mature protein produced three bands, while the probe containing DNA for the N-terminal end of the mature protein produced five hybridization bands. This suggested that the antigen 85 complex of M. avium might consist of more than three, and probably five, structurally related components. We have been unable to identify more than three bands with other species of mycobacteria (i.e., M. bovis BCG, M. kansasii, M. intracellulare, M. szulgai, M. simiae, M. scrofulaceum, and M. mannum) examined to date. However, the considerations described above for M. avium do not seem to be exceptional. The finding that the 27-kDa MTP51 protein from M. tuberculosis immunologically cross-reacted with all three components of the antigen 85 complex and that the N-terminal amino acid sequences of MTP51 and T-ot showed 60% homology (20) . Immunoblot analysis of A-a fusion proteins expressed in E. coli reacted with absorbed anti-A-a serum. Lanes: 1, size markers; 2, pUR291 (control); 3, pMAA1; 4, pMAA2; 5, pMAA3; 6, pMAA4; 7, pMAA5; 8, pMAA6; 9, pMAA7; 10, pMAA8; 11, pMAA9. Numbers at the left indicate molecular mass (in kilodaltons). identical to that of A-a purified from the culture filtrate ofM. avium. A comparison of the amino acids of A-ca revealed a higher sequence similarity to the at antigen (B component of antigen 85 complex) from M. bovis BCG (82%) (18) than to the A and C components from M. tuberculosis or M. bovis BCG (64 and 72%) (4, 8, 10) . The A components from M. tuberculosis and from M. bovis BCG were identical except for a silent single nucleotide change at position 1023 (10). Promoter-like sequences and the Shine-Dalgarno sequence were absolutely identical with those of M. leprae. However compared with other a-antigen species, fewer homologies were seen at Ser-147 to Asp-181 and Gly-320 to Gly-330.
On the basis of antiserum reactivity patterns with the fusion proteins, the putative epitopes were mapped at six distinct regions. The amino acid regions Leu-51 to Tyr-123, Gly-169 to and least three epitopes which were common to M. tuberculosis, M. kansasii, and M. avium. Also, at least three epitopes unrelated to T-a were mapped on the Gly-169 to Leu-203, Gly-252 to Glu-305, and Leu-318 to Gly-330 amino acid sequences. The ax antigen is a cross-reacting antigen which is widely distributed in mycobacteria. The cross-reactivities were previously examined by the agar gel diffusion technique in detail (25) (26) (27) . T-a and a antigen from M. bovis BCG were serologically identical, whereas the other mycobacteria (M. avium-M. intracellulare complex, M. scrofulaceum, M. gordonae, M. szulgai, M. kansasii, and M. marinum) possessed common antigenic determinants and species-specific antigenic determinants. From these considerations, we can draw the conclusion that A-a may possess three speciesspecific epitopes. The carboxyl-terminal region, which was probably a species-specific epitope, has a Pro residue at position 326, which predicted occasional involvement of a 0-tum potential in an antigenic site (11) . Pro-326 was replaced with positively charged Arg (pMAA91), and the reactivity with the anti-A-ao serum was examined. The expressed protein with the amino acid substitution resulted in little loss of recognition by the anti-A-a serum. A deletion mutant, which encoded 318-LeuGlnGlyThrLeuGlyAlaSer-325, was constructed (pMAA92) and expressed. The expressed protein containing these amino acids resulted in no recognition of the anti-A-a serum. These results suggested that Gly-327 to Gly-330 required for the recognition by the serum.
To our knowledge, this is the first report on the epitope mapping of a component of mycobacterial antigen 85 complex. The precise mapping of B-cell and T-cell epitopes with synthetic peptides is under way. It is hoped that these studies will be valuable in furthering the understanding of protective and pathologic immunities as well as in diagnosis and vaccine development.
